Forward Pharma
Vibeke Ackermann is an experienced finance professional currently serving as the European Group Controller at Forward Pharma A/S since October 2018. Previously, Vibeke held various significant roles at GE Healthcare, including Commercial Finance Manager for Denmark and Head of Finance for GE Healthcare Clinical Systems A/S, where responsibilities included establishing the finance department post-acquisition. Earlier experience includes serving as an Asset Manager at DONG Energy and as a Revisor at KPMG and Centralanstalten for Revision. Vibeke's educational background includes multiple degrees from Copenhagen Business School in Business Economics & Auditing and Financial & Management Accounting, as well as a diploma in commerce and a certified youth pedagogue diploma.
This person is not in the org chart
This person is not in any teams
Forward Pharma
1 followers
Forward Pharma A/S is a Danish biopharmaceutical company that commenced development in 2005 of a proprietary formulation of DMF for the treatment of inflammatory and neurological indications. The Company granted to Biogen an irrevocable license to all of its IP through the License Agreement and received from Biogen a non-refundable cash fee of $1.25 billion in February 2017, with the return of EUR 917.7 million to shareholders through a capital reduction in September 2017. The Company has the opportunity to receive royalties from Biogen on Biogen’s net sales of Tecfidera® or other DMF products for multiple sclerosis outside the U.S., dependent on, among other things, a favorable outcome in Europe with respect to the ‘355 Patent Opposition Proceeding, including any appeal thereto.